| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) treatment of HIV in adults who are virologically suppressed | PDUFA | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | |
PDUFA Date example | bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) treatment of HIV in adults who are virologically suppressed | PDUFA | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | |
PDUFA Date example | bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) treatment of HIV in adults who are virologically suppressed | PDUFA | — | Subscribe to access the data. | Small Molecules | Infectious Diseases |
Recent Updates
Recently added Catalysts
Gilead Sciences, Inc.$129.83
-5.01 (-3.72%)
A 92Pipeline Score Fair Value Biotech · Commercial
Market Cap
166.82 B
EPS
7.41
P/E Ratio
18.28 $
Value Trade
804.39 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.96 B
R&D Expenses
1.37 B
Operating CF
2.54 B
Total Assets
56.28 B
Total Liabilities
56.28 B
Equity
23.52 B
D/E Ratio
12,345
1.58 %
Week
0.5 %
1 Month
-10.77 %
3 Month
7.2 %
6 Month
92.58 %
5 Year
24,824.73 %
All Time
Cash Data
Cash Position
7.63 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
5.94 M
52 Week Range
104.46 - 157.29
% held by Insiders
0.14 %
% held by Institutions
90.18 %
Enterprise Value
179.09 B
Total Shares
1.24 B
Short %
2.75 %
Float Shares
926.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Gilead Sciences, Inc.
470Total events
16Upcoming
224Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 16
TBD
T2Other Regulator Milestone
Engagement with global regulatory authorities to discuss IDEAL results
TBD
T1Partnership / License
Gilead in advanced discussions with Galapagos for collaboration on Ouro assets
TBD
T1NDA Submission
Supplemental applications submitted to FDA for approval based on ASCENT-03 and ASCENT-04 studies
TBD
T2Timing Guidance
Assembly Bio eligible for up to $330 million in regulatory and commercial milestones
Event history 454
Jun 29, 2026
Jun 24, 2026
▲FDA ApprovalTrodelvyDiscontinuedFDA Decision
FDA approval for first-line treatment of mTNBC
metastatic triple-negative breast cancersource ↗
Jun 23, 2026
▲EU ApprovalTrodelvyDiscontinuedEx-US Regulatory
European Commission approves Trodelvy as first-line treatment for metastatic triple-negative breast cancer patients not candidates for PD-(L)1 inhibitors
metastatic triple-negative breast cancersource ↗
Jun 15, 2026
▲FDA Filing AcceptedYeztugoApprovedRegulatory Filing
FDA accepts NDA for Yeztugo
HIV preventionsource ↗
Jun 13, 2026
◆Poster PresentationKITE-753Presentation
Updated safety and efficacy results of KITE-753
relapsed/refractory B-cell lymphomasource ↗
Jun 13, 2026
◆Poster Presentationbrexu-celPresentation
Cost-effectiveness analysis of brexucabtagene autoleucel in Singapore
relapsed or refractory B-cell precursor acute lymphoblastic leukemiasource ↗
Jun 13, 2026
◆Poster PresentationPresentation
Follow-up-time-adjusted non-relapse mortality following CAR T-cell therapy within clinical trials
non-Hodgkin lymphomasource ↗
Jun 13, 2026
◆Poster Presentationanito-celPresentation
Anito-cel clinical trial manufacturing experience
relapsed/refractory or newly diagnosed multiple myelomasource ↗
Jun 13, 2026
◆Poster PresentationAxi-celPresentation
Cost-effectiveness of axi-cel in Taiwanese patients after first-line treatment
relapsed/refractory diffuse large B-cell lymphoma and high-grade B-cell lymphomasource ↗
Jun 12, 2026
◆Poster PresentationAxi-celPresentation
Cost-effectiveness of axi-cel in Taiwanese patients after two lines of systemic therapy
relapsed/refractory diffuse large B-cell lymphomasource ↗
Jun 12, 2026
◆Poster PresentationPresentation
CAR T-cell therapy in clinical routine: quantification of real-world hospital resource use in Germany
non-Hodgkin lymphomasource ↗
Drug Pipeline Intelligence
A92
Pipeline Score $121.4B
Pipeline ValueFair Value
Valuation Signal193
Drugs Scored2.4x
rNPV / MCap Top 99%
Large Pharma (rank 10 of 912)
Percentile RankGilead Sciences, Inc. earns an A-grade pipeline score (92/100), with $121.4B risk-adjusted pipeline value, led by Ranolazine in Type 2 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranolazine Small molecule | Angina | Phase 3 | NCT02265796 | 55% | $13.6B | COMPLETED | 561 | - | - | Sep 1, 2016 | - | Aug 22, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Islatravir/Lenacapavir | HIV | Phase 3 | 2026-06-08 | In the Phase 3 studies, Islatravir/Lenacapavir demonstrated significant efficacy with a 92% virologic suppression rate at week 48, achieving a p-value of <0.001 compared to the control group. Read More | Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment Read More | |
Islatravir/Lenacapavir | HIV | Phase 3 | 2026-06-08 | In the Phase 3 studies, Islatravir/Lenacapavir demonstrated significant efficacy with a 92% virologic suppression rate at week 48, achieving a p-value of <0.001 compared to the control group. Read More | Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment Read More | |
Islatravir/Lenacapavir | HIV | Phase 3 | 2026-06-08 | In the Phase 3 studies, Islatravir/Lenacapavir demonstrated significant efficacy with a 92% virologic suppression rate at week 48, achieving a p-value of <0.001 compared to the control group. Read More | Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GILD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GILD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GILDU.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Gilead Sciences announced that the FDA has approved Trodelvy for first-line treatment of metastatic triple-negative breast cancer (mTNBC). This approval allows Trodelvy to be used as a single agent for patients who cannot undergo surgery. The drug is a Trop-2-directed antibody-drug conjugate, marking a significant advancement in treatment options for this patient population.
Read more →GILDEuropean Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
The European Commission has approved Trodelvy® as a first-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for PD-(l)1 inhibitors. This approval offers a new therapeutic option for a challenging patient population, enhancing treatment accessibility and potential outcomes.
Read more →GILDU.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
The U.S. FDA has accepted Gilead's application for Yeztugo, an investigational once-weekly oral medication. If approved, Yeztugo could be the first long-acting pill for HIV prevention, potentially improving adherence among patients. This development marks a significant step in HIV prevention strategies.
Read more →GILDGilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Gilead and Merck have reported positive topline results from two Phase 3 studies evaluating Islatravir/Lenacapavir, a new oral treatment for HIV. This treatment is designed to be taken once weekly, potentially improving adherence among patients. The results indicate significant efficacy, marking a promising advancement in HIV therapy.
Read more →GILDGilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Gilead's Livdelzi® (seladelpar) has demonstrated statistically significant composite alkaline phosphatase (ALP) normalization in the Phase 3 IDEAL trial for patients with Primary Biliary Cholangitis (PBC). This result indicates a promising advancement in the treatment of PBC, potentially enhancing patient outcomes. The trial's findings may lead to broader therapeutic applications for Livdelzi®.
Read more →GILDGermany can produce biotech winners. Europe must back them better.
Germany is positioned to produce biotech champions due to its strong scientific infrastructure and capital availability, as evidenced by Gilead's acquisition of Tubulis. However, to enhance its global competitiveness, the country requires deeper funding pools and more flexible investment regulations. The collaboration between local and international investors is crucial for scaling successful biotech companies.
Read more →GILDThe top 5 highest paid pharma CEOs in 2025
In 2025, the top five highest paid pharma CEOs earned a combined $157.8 million, marking a 24% increase from the previous year. Eli Lilly's David Ricks led with a compensation of $36.7 million, driven by significant company growth and stock awards. Other notable CEOs include J&J's Joaquin Duato and AbbVie's Robert Michael, who also saw substantial pay increases amid industry pressures.
Read more →GILDPhase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
The article discusses interim data from the Phase 3 ASSURE study regarding Gilead's Livdelzi (Seladelpar). The data indicates that a majority of participants with ALP levels between 1-1.67×ULN achieved high and sustained normalization of composite ALP at 24 months. However, the article lacks detailed insights or specific outcomes.
Read more →GILDFDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
The FDA has granted accelerated approval to Gilead's Hepcludex® (bulevirtide-gmod), marking it as the first and only approved treatment for chronic Hepatitis Delta Virus (HDV). This approval is expected to provide a new therapeutic option for patients suffering from this condition. The accelerated pathway highlights the urgency and importance of addressing this unmet medical need.
Read more →GILDGilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Gilead Sciences has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding Trodelvy® for first-line treatment of metastatic triple-negative breast cancer. This recommendation specifically targets patients who are not candidates for PD-(L)1 inhibitors, highlighting the potential of Trodelvy® in addressing unmet medical needs in this patient population.
Read more →GILDGilead inks $140M API supply deal, tightening ties to Korean manufacturer
Gilead Sciences has entered a $139.8 million agreement with South Korean manufacturer Yuhan to source active pharmaceutical ingredients (APIs). This deal, effective from May 19 until the end of next year, strengthens Gilead's ongoing collaboration with Yuhan, which has previously supplied APIs for Gilead's HIV and hepatitis C drugs. The contract represents a notable portion of Yuhan's annual sales.
Read more →GILDNew ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
The article discusses Gilead and Kite's progress in oncology, particularly focusing on their advancements in antibody-drug conjugates and cell therapy. It highlights data presented at ASCO and EHA 2026, showcasing their ongoing momentum in these therapeutic areas. However, specific details regarding the data or outcomes are not provided.
Read more →GILDGilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Gilead Sciences has finalized its acquisition of Tubulis, a strategic move aimed at bolstering its oncology portfolio. This acquisition is expected to enhance Gilead's capabilities in cancer treatment and improve its competitive standing in the oncology market. The completion of this deal marks a significant step in Gilead's growth strategy.
Read more →GILDGilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Gilead Sciences has announced an expanded collaboration with the World Health Organization (WHO) to address visceral leishmaniasis, a severe parasitic disease. The initiative focuses on eliminating this disease, which poses significant health risks in affected regions. This partnership aims to enhance treatment and prevention efforts globally.
Read more →GILDGilead Prices $3 Billion of Senior Unsecured Notes
Gilead has announced the pricing of $3 billion in senior unsecured notes. This financial move is part of the company's strategy to manage its capital structure. The notes will likely be used for general corporate purposes, although specific uses have not been detailed in the announcement.
Read more →GILDGilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
Gilead Sciences is set to present new data related to primary biliary cholangitis (PBC) and viral hepatitis at the upcoming EASL 2026 event. The presentation aims to highlight advancements in care for these conditions. Further details on the specific data to be presented have not been disclosed in the article.
Read more →GILDGilead sets blockbuster bar for Yeztugo’s first full year on the market
Gilead anticipates $1 billion in sales for its PrEP injection Yeztugo in its first full year. The product has shown remarkable growth, with a 72% increase in revenue from the previous quarter. Healthcare professionals report improved patient experiences, and the drug is gaining traction among both naive and switching patients. Gilead also discussed the potential approval of anito-cel for multiple myeloma.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion Foster City, CA
Gilead Sciences reported an 8% increase in product sales excluding Veklury, totaling $6.8 billion for Q1 2026. The increase was driven by a 10% growth in HIV products, particularly Biktarvy, which saw sales rise to $3.4 billion. However, Veklury sales plummeted 52% due to declining hospitalizations related to COVID-19. Gilead also updated its full-year guidance, reducing earnings expectations due to anticipated charges related to recent acquisitions.
Read more →GILDGilead Sciences Announces First Quarter Financial Results
Gilead Sciences has announced its financial results for the first quarter. The report details the company's performance metrics, but specific figures and insights are not provided in the article. Further analysis may be required to understand the implications of these results on Gilead's future.
Read more →GILDGilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
Gilead Sciences, Inc. announced its participation in several upcoming investor conferences, including the BofA Securities Health Care Conference and the RBC Capital Markets Global Healthcare Conference. Executives will present on various dates in May and June 2026. Live webcasts of the presentations will be available on the company's investor page.
Read more →GILDU.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
Gilead Sciences announced that the FDA has accepted its New Drug Application for bictegravir 75 mg/lenacapavir 50 mg, a once-daily single-tablet combination treatment for HIV. The FDA has granted priority review, with a PDUFA action date set for August. This treatment is aimed at adults who are already virologically suppressed.
Read more →GILDGilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
Gilead Sciences has successfully completed its acquisition of Arcellx for $115 per share, totaling approximately $7.8 billion. This acquisition grants Gilead full control over anito-cel, a CAR T-cell therapy for multiple myeloma, allowing for accelerated development and decision-making. Gilead anticipates this transaction will be modestly dilutive to earnings in the short term but accretive thereafter, pending FDA approval.
Read more →GILDAshleigh Koss, Media Public_affairs@gilead.com Jacquie Ross, Investors investor_relations@gilead.com GILEAD SCIENCES COMPLETES ACQUISITION OF ARCELLX AHEAD OF POTENTIAL COMMERCIAL LAUNCH OF ANITO-CEL
Gilead Sciences has successfully completed its acquisition of Arcellx for approximately $7.8 billion, as it prepares to launch anito-cel, a new CAR T-cell therapy for multiple myeloma. The transaction was completed through a merger, making Arcellx a wholly owned subsidiary of Gilead. Although the acquisition will reduce Gilead's earnings per share in the immediate term, it is expected to be accretive by 2028, pending FDA approval for anito-cel. Gilead's leadership highlighted the strategic value of Arcellx's scientific capabilities and technology.
Read more →GILDGilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
Gilead Sciences has announced the release date for its first quarter 2026 financial results, which will occur on Thursday, May 7, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will be provided at that time.
Read more →GILDGilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
Gilead has received all required regulatory approvals for its acquisition of Arcellx. The company is extending its tender offer, showcasing its commitment to the acquisition. This development marks a significant step forward for Gilead in expanding its portfolio.
Read more →GILDPEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
Gilead Sciences announced a new investment from PEPFAR and The Global Fund to expand access to its HIV prevention drug, lenacapavir, for an additional 1 million people over the next three years. This commitment brings the total number of people served to 3 million in resource-limited countries by 2028. Gilead aims for a large-scale generic rollout of lenacapavir starting in 2027.
Read more →GILDGilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Gilead Sciences has announced its acquisition of Tubulis, aiming to enhance its oncology pipeline with potentially best-in-class antibody-drug conjugates. This strategic move is expected to strengthen Gilead's position in cancer treatment and expand its drug development capabilities. The acquisition reflects Gilead's commitment to advancing innovative therapies in oncology.
Read more →GILDGilead Extends Tender Offer to Acquire Arcellx
Gilead Sciences has extended its tender offer to acquire Arcellx, now set to expire on April 24, 2026. The offer includes a cash payment of $115.00 per share and a contingent value right for an additional $5.00, contingent on sales milestones. Approximately 7.5% of Arcellx shares have been tendered so far. The transaction is expected to close in Q2 2026, pending regulatory approvals and other conditions.
Read more →GILDGilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
This week in biopharma, Gilead announced a $2.1 billion acquisition of Ouro Medicines, focusing on T cell engagers. Johnson & Johnson and Protagonist Therapeutics celebrated FDA approval for their IL-23 receptor blocker, Icotyde, which is Protagonist's first commercial product. Meanwhile, Aurinia Pharmaceuticals appointed Kevin Tang as CEO amidst industry drama, and the CDC faced confusion regarding its Advisory Committee on Immunization Practices.
Read more →GILDGilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Gilead Sciences has announced its acquisition of Ouro Medicines to enhance its inflammation portfolio with the clinical-stage T cell engager OM336. This therapy has shown promising efficacy in treating autoimmune diseases and has received Fast Track and Orphan Drug Designations from the FDA. Gilead also plans to collaborate with Galapagos on the Ouro portfolio, aiming to expedite development and commercialization.
Read more →GILDGilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club
Gilead CEO Daniel O'Day received a 20% pay increase, totaling $28.44 million in 2025. His compensation package was largely driven by stock awards and incentives. Under his leadership, Gilead achieved significant milestones, including the approval of the HIV prevention pill Yeztugo, which is projected to generate $800 million in sales this year. However, O'Day's pay remains below that of several peers in the industry.
Read more →GILDGilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos
Gilead Sciences has announced its acquisition of Ouro Medicines for up to $2.1 billion, with an upfront payment of $1.675 billion and potential milestone payments. The company is negotiating with Galapagos to share the financial burden, which would alleviate Gilead's upfront and R&D costs. OM336, Ouro's lead candidate, has received FDA designations and is currently in early-stage studies.
Read more →GILDGilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
Gilead Foundation has announced a $12 million investment aimed at enhancing HIV prevention efforts through community health workers across 14 states and the District of Columbia. This initiative focuses on empowering local organizations to provide tailored education and services to communities most affected by HIV. The funding will support integrated screening and reduce stigma while building long-term capacity in the community health workforce.
Read more →GILDDeep Dive: BioSpace Takes On JPM26 in San Francisco
The J.P. Morgan Healthcare Conference revealed key themes such as innovation in China, neuroscience advancements, and a notable absence of major mergers and acquisitions. Discussions highlighted the importance of vaccine business development and the shifting landscape of obesity treatments. Despite some setbacks, the focus on early-stage science and regulatory alignment indicates a positive outlook for the industry.
Read more →GILDGilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
Gilead Sciences announced positive results from the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, showcasing the efficacy of a single-tablet regimen combining bictegravir and lenacapavir for HIV treatment. The regimen was effective in maintaining virological suppression among participants who switched from complex multi-tablet regimens. The findings suggest that BIC/LEN could offer a new, well-tolerated treatment option for adults living with HIV.
Read more →GILDGilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
Gilead and Merck are advancing their daily HIV pills towards market launch, supported by new Phase 3 data presented at CROI 2026. Gilead's BIC/LEN showed sustained virologic suppression comparable to existing treatments. Meanwhile, Merck's DOR/ISL also demonstrated strong efficacy but may struggle against Gilead's established market dominance. Regulatory submissions for both drugs are anticipated soon.
Read more →GILDGilead Sciences to Present at Upcoming March 2026 Investor Conferences
Gilead Sciences, Inc. will present at several investor conferences in March 2026. The company's executives will provide insights into their ongoing efforts in advancing innovative medicines. Live webcasts of the presentations will be available on their investor page, with replays accessible for 30 days post-event. Gilead continues to focus on treating life-threatening diseases globally.
Read more →GILDGilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
Gilead Sciences has announced its acquisition of Arcellx for $7.8 billion, aiming to leverage the potential of anito-cel, a CAR T-cell therapy for multiple myeloma. The transaction, which includes a cash offer and contingent value rights, is expected to close in Q2 2026, pending regulatory approvals. Anito-cel has shown promising clinical results, and Gilead anticipates the acquisition will enhance its oncology portfolio.
Read more →GILDGilead Doubles Down on CAR T With $7.8B Arcellx Acquisition
Gilead Sciences has announced its acquisition of Arcellx for $7.8 billion, valuing the company at $115 per share. This move comes ahead of the potential FDA approval of an investigational CAR T therapy, anito-cel, which targets multiple myeloma. The acquisition is expected to close in Q2 2024 and reflects Gilead's commitment to expanding its oncology portfolio.
Read more →GILDGilead Ashleigh Koss, Media public affairs@gilead.com Jacquie Ross, Investors investor relations@gilead.com Arcellx Kristalle Cooks, Media pr@Arcellx.com Myesha Lacy, Investors ir@Arcellx.com GILEAD SCIENCES TO
Gilead Sciences has announced a definitive agreement to acquire Arcellx for $115 per share, positioning itself to fully control Anito-cel, a promising CAR T-cell therapy for multiple myeloma. This acquisition builds on a previous successful collaboration between the two companies and allows Gilead to streamline development and commercialization efforts. Anito-cel has shown potential in clinical studies, with the FDA accepting the Biologics License Application for future use. The transaction, valued at approximately $7.8 billion, is expected to close in the second quarter of 2026, subject to regulatory approvals.
Read more →GILDGilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
Gilead Sciences announced it will present new data on HIV treatment and prevention at CROI 2026. Key highlights include Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials, demonstrating the efficacy of a new single-tablet regimen. The company aims to broaden options for HIV treatment and prevention, addressing diverse community needs.
Read more →GILD▲ +5.8%on this newsshared move
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
Gilead Sciences reported a 4% increase in product sales for 2025, totaling $28 billion, driven by strong performance in HIV and liver disease products. The successful launch of Yeztugo marks a significant achievement in HIV prevention. Despite challenges with Veklury sales and competitive pressures in cell therapy, Gilead anticipates further growth in 2026 with new product launches planned.
Read more →GILD▲ +5.8%on this newsshared move
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
Gilead Sciences has announced a 3.8% increase in its quarterly cash dividend, raising it to $0.82 per share starting in the first quarter of 2026. This decision reflects the company's ongoing financial strength and commitment to shareholder returns. The dividend will be payable on March 30, 2026, to stockholders of record by March 13, 2026.
Read more →GILD▲ +5.8%on this newsshared move
Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority
Gilead is taking a proactive and disciplined approach to mergers and acquisitions, indicating that while it may consider deals, there is no urgency. The company boasts a strong product pipeline, including the successful launch of Yeztugo, which is projected to grow significantly. Gilead's revenue for 2025 showed a slight increase, with notable growth in its HIV segment.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over
Gilead Sciences reported its financial results for Q4 and full year 2025, highlighting a 5% revenue increase in Q4, primarily driven by strong sales in HIV and liver disease products. Biktarvy sales saw a 7% growth, and the company successfully launched Yeztugo, an innovative HIV prevention therapy. Despite these positives, Veklury sales notably decreased by 37%, attributed to a reduction in COVID-19 hospitalizations. The overall outlook remains optimistic for further growth in 2026 with upcoming product launches.
Read more →GILDFDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
The FDA has approved an update to the prescribing information for Kite's Yescarta, removing previous limitations for its use in patients with relapsed or refractory primary central nervous system lymphoma (PCNSL). This decision is based on a Phase 1 study demonstrating the safety of Yescarta in this patient population. The update is significant as it provides clinicians with crucial evidence for treating patients with a historically poor prognosis and limited options.
Read more →GILDGilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
Gilead Sciences, Inc. will announce its fourth quarter and full year 2025 financial results on February 10, 2026. Following the release, a webcast will be held at 4:30 p.m. ET to discuss the results and provide a business update. Gilead continues to focus on innovative treatments for life-threatening diseases.
Read more →GILDNew England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
Gilead Sciences announced that the Phase 3 ASCENT-04/KEYNOTE-D19 study results, published in NEJM, show that Trodelvy combined with Keytruda significantly improves progression-free survival in first-line PD-L1+ metastatic triple-negative breast cancer compared to standard chemotherapy. The combination therapy reduced the risk of disease progression or death by 35%. Despite promising results, the safety and efficacy of this combination remain investigational.
Read more →GILDJPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
At the J.P. Morgan Healthcare Conference, Gilead's CEO Daniel O'Day expressed optimism about the company's HIV drug Yeztugo, which has achieved 85% payer coverage within six months of its launch. Gilead plans to expand its market reach and is exploring new oncology opportunities. The company is also focusing on improving access to its medications through voluntary licensing.
Read more →GILDGilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Gilead Sciences has exercised its option to license Assembly Biosciences' helicase-primase inhibitor programs for recurrent genital herpes, specifically ABI-1179 and ABI-5366. This collaboration aims to address the unmet needs of over four million people suffering from recurrent genital herpes. Positive interim data from Phase 1b trials indicate strong antiviral activity and favorable dosing profiles for these investigational candidates.
Read more →GILDGilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Gilead Sciences has entered a three-year agreement with the U.S. government to lower drug costs for Americans, addressing all requests made by President Trump. The agreement emphasizes Gilead's commitment to U.S. innovation and includes a significant investment of $32 billion in manufacturing and R&D. This initiative is expected to create over 3,000 jobs and enhance America's leadership in global health.
Read more →GILDKite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
Kite, a Gilead Company, presented promising Phase 1 results for its bicistronic CAR T-cell therapies, KITE-753 and KITE-363, targeting relapsed/refractory large B-cell lymphoma. KITE-753 showed a 79% complete response rate in CAR-naïve patients, while KITE-363 demonstrated durable benefits at higher doses. Both therapies exhibited favorable safety profiles, suggesting potential for broader patient access.
Read more →GILDKite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
Kite, a Gilead Company, presented new data from the pivotal iMMagine-1 Phase 2 study of anito-cel at the ASH Annual Meeting. The study demonstrated a 96% overall response rate and a 95% minimal residual disease negativity among relapsed or refractory multiple myeloma patients. The safety profile was manageable, with no delayed neurotoxicities reported. Kite plans to launch anito-cel in the U.S. in 2026.
Read more →GILDYescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
Kite, a Gilead Company, presented new analysis at ASH 2025 showing that Yescarta therapy provides consistent benefits for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), including those ineligible for standard treatments. The findings from the ZUMA-7 and ALYCANTE studies highlight Yescarta's efficacy and safety, suggesting it should be considered earlier in treatment protocols. Patients reported significant improvements in quality of life post-treatment.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion Biktarvy Sales Increased 6% Year-Over-Year to $3.7 billion Foster City,
Gilead Sciences reported its third quarter 2025 financial results, highlighting a 4% increase in product sales excluding Veklury, reaching $7.1 billion, with Biktarvy sales increasing by 6% to $3.7 billion. Despite a 2% decline in total product sales primarily driven by lower Veklury and Cell Therapy sales, the company maintains a positive outlook with a robust pipeline and multiple anticipated product launches in 2026. Gilead also received strong endorsements for its HIV prevention product Yeztugo. However, it faced significant declines in Veklury sales due to lower COVID-19 related hospitalizations.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion Foster City,
Gilead Sciences reported its second-quarter 2025 financial results, highlighting a 4% increase in product sales excluding Veklury, totaling $6.9 billion. The company achieved notable growth in its HIV segment, particularly with Biktarvy and Descovy. The recent FDA approval of Yeztugo marks a significant milestone as it serves as the first twice-yearly HIV prevention option. Despite these successes, Veklury sales experienced a substantial decline, and the company reported higher R&D expenses impacting its earnings.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion Foster City,
Gilead Sciences announced its first quarter 2025 financial results, highlighting a 4% year-over-year increase in product sales excluding Veklury. The company's total revenue remained flat at $6.7 billion, impacted by decreased sales of Veklury and Oncology products. The strong performance of Biktarvy, which saw a 7% increase in sales, helped offset these declines. Gilead also reported positive Phase 3 results for Trodelvy combined with pembrolizumab in a breast cancer study, while preparing for the anticipated approval of lenacapavir for HIV prevention in June.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024 Biktarvy Sales Increased 13% Year-Ove
Gilead Sciences announced its fourth quarter and full year 2024 financial results, showing a strong overall performance with an 8% increase in product sales, excluding Veklury. Notably, sales of Biktarvy and oncology products rose significantly, contributing to the growth. However, Veklury sales fell sharply, affecting the overall EPS, which saw a decrease compared to the previous year. Looking forward, Gilead is preparing for the upcoming launch of lenacapavir for HIV pre-exposure prophylaxis.
Read more →GILDAshleigh Koss, Media public_affairs@gilead.com Jacquie Ross, Investors investor_relations@gilead.com GILEAD SCIENCES APPOINTS DIETMAR BERGER, MD, PHD, AS CHIEF MEDICAL OFFICER Foster City, Calif.
Gilead Sciences has announced the appointment of Dietmar Berger, MD, PhD, as its new Chief Medical Officer, effective January 2, 2025. Berger, with over 25 years of experience in drug development, previously held the position at Sanofi and has a notable record in advancing innovative therapies. He will oversee Gilead's portfolios in virology, oncology, and inflammation, succeeding Merdad Parsey. Gilead's leadership expresses confidence in Berger's ability to enhance their impact on patient health outcomes globally.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sal
Gilead Sciences reported its Q3 2024 financial results, showcasing a 7% year-over-year revenue growth to $7.5 billion, driven by solid performance in HIV and Oncology. Biktarvy sales increased by 13%, contributing significantly to this growth. Despite the positive financial outlook, Gilead experienced a decline in diluted EPS due to a large impairment charge. The company is also set to enhance its product offerings with the anticipated launch of lenacapavir for HIV prevention.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sal
Gilead Sciences announced its second quarter 2024 financial results, showcasing a 6% year-over-year increase in product sales, totaling $6.7 billion. Notable contributors to this growth were Biktarvy and oncology therapies, with Biktarvy sales rising 8% to $3.2 billion. The company also reported 100% efficacy for lenacapavir in HIV prevention from a recent Phase 3 trial. However, it experienced a decline in Veklury sales by 16%, attributed to reduced COVID-19 hospital admissions. Gilead's cash reserves reduced significantly due to an acquisition and debt repayment.
Read more →GILDResearch Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore With the advancements in medical sciences, there is now very little difference between the life expectancy of people with HIV (PWH) and the general...
Gilead Sciences conducted research in Singapore revealing three blind spots affecting the quality of life for people with HIV (PWH). These include a focus on short-term physical health over mental health, low awareness of chronic disease risks, and passive communication with healthcare providers. To address these issues, Gilead launched the My Care Diary app to promote proactive health management.
Read more →GILDAshleigh Koss, Media Public_affairs@gilead.com Jacquie Ross, Investors investor_relations@gilead.com CHIEF MEDICAL OFFICER MERDAD PARSEY TO LEAVE GILEAD EARLY 2025 Foster City, Calif.
Gilead Sciences announced that Chief Medical Officer Merdad Parsey will depart the company in early 2025 after five years of leadership. Under his tenure, Gilead successfully doubled its portfolio and initiated 54 clinical trials across various disease areas. As the company seeks a successor, Parsey will support the transition until Q1 2025. His contributions significantly shaped Gilead's advancements in virology and oncology, enhancing the company's diverse clinical pipeline.
Read more →GILDNEW DATA SUPPORT THE USE OF BICTEGRAVIR TABLET REGIMEN TO TREAT PEOPLE WITH HIV AND INDIVIDUALS WITH HIV/HBV-COINFECTION IN ASIA – Multiregional Study Across Taiwan, South Korea, and Singapore Supports Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)...
Gilead Sciences presented new data at the APACC 2024 conference, highlighting the efficacy and tolerability of the B/F/TAF single-tablet regimen for treating adults with HIV and HIV/HBV co-infection in Asia. The studies demonstrated high effectiveness in suppressing viral loads and improving mental health outcomes among participants. These findings emphasize the importance of tailored treatment strategies for diverse ethnic groups.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sal
Gilead Sciences, Inc. disclosed its financial results for the first quarter of 2024, showing a 5% increase in total revenue to $6.7 billion driven largely by growth in HIV, oncology, and liver disease product sales. Notably, Biktarvy sales surged 10% year-over-year, while oncology sales rose 18%. However, the company faced a significant diluted earnings per share loss due to a $3.9 billion charge related to the acquisition of CymaBay Therapeutics. The guidance for the full year remains unchanged, despite the noted challenges in cash reserves and specific product sales declines.
Read more →GILDGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support...
Gilead Sciences has announced a $4 million global distribution through its ALL4LIVER Grant to support innovative projects targeting viral hepatitis elimination. The funding will empower two Indian organizations, Chennai Liver Foundation and FIND, to enhance testing and treatment efforts. This initiative aligns with the WHO's goal to eliminate viral hepatitis as a public health threat by 2030.
Read more →GILDGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support...
Gilead Sciences has announced a $4 million global distribution through its ALL4LIVER Grant to support innovative community projects aimed at eliminating viral hepatitis by 2030. This funding, awarded to 71 organizations, includes initiatives in Asia led by the Association of Liver Patients and Survivors and the Taiwan Formosa Cancer Foundation. The grant aims to improve testing, care linkage, and public health awareness regarding hepatitis B, C, and D.
Read more →GILDGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support...
Gilead Sciences has announced a $4 million global distribution through its ALL4LIVER Grant to support community-led initiatives aimed at eliminating viral hepatitis by 2030. The grant will fund projects in Hong Kong, including a city-wide liver health screening program and an awareness campaign. This initiative is part of Gilead's ongoing efforts to combat viral hepatitis globally.
Read more →GILD吉利德科學與世界肝炎聯盟及專家攜手透過 ALL4LIVER基金全球撥款400萬美元支持世衛2030年的滅肝目標，兩間香港非牟利組織受惠 吉利德科學(吉利德)於世界肝炎峰會（「峰會」）舉行的同時宣布，將通過其ALL4LIVER基金（「基金」）全球撥款400萬美元，以支持與丙型肝炎、乙型肝炎和丁型肝炎相關的社區創新項目。由世界肝炎聯盟主辦的世界肝炎峰會於2024年4月9日至11日在裡斯本舉行，吉利德在峰會上舉辦以「共建全球健康公平：案例...
Gilead Sciences has announced a 400 million USD commitment through its ALL4LIVER fund to support global efforts in eliminating hepatitis by 2030. This initiative will focus on various hepatitis types and aims to enhance community awareness and treatment accessibility. The announcement coincides with the World Hepatitis Summit, highlighting the importance of collaborative efforts in combating hepatitis globally.
Read more →GILDInvestors: Jacquie Ross investor relations@gilead.com Media: Ashleigh Koss public affairs@gilead.com GILEAD SCIENCES ANNOUNCES COMPLETION OF ACQUISITION OF CYMABAY Acquisition Reinforces Gilead's Leadership in
Gilead Sciences, Inc. has successfully completed its acquisition of CymaBay Therapeutics for approximately $4.3 billion. The acquisition is expected to enhance Gilead's therapeutic offerings, particularly with CymaBay's lead candidate, seladelpar, aimed at treating primary biliary cholangitis. However, seladelpar remains investigational and has not yet received regulatory approval. The deal is projected to impact Gilead's earnings per share for 2024 adversely, accounting for significant acquisition costs.
Read more →GILDGilead Investors: Jacquie Ross investor_relations@gilead.com Media: Ashleigh Koss public_affairs@gilead.com CymaBay Investors: PJ Kelleher LifeSci Advisors, LLC pkelleher@LifeSciAdvisors.com Media: Arran Attrid
Gilead Sciences has announced its acquisition of CymaBay Therapeutics for $4.3 billion, specifically to enhance its liver disease portfolio with CymaBay's investigational product, seladelpar, for treating primary biliary cholangitis (PBC). The FDA has granted priority review for seladelpar, which shows promising clinical data, enhancing prospects for Gilead's liver disease treatments. The transaction is expected to close in Q1 2024, pending regulatory approvals, and aims to significantly boost Gilead's revenue growth, although it carries typical merger risks.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for
Gilead Sciences announced its fourth quarter and full year 2023 financial results, reporting a year-over-year increase in product sales, excluding Veklury, by 7%. Biktarvy and oncology segments showed strong performance, with sales rising by 14% and 37%, respectively. However, total revenue declined by 4% in the fourth quarter, largely due to a significant decrease in Veklury sales. Gilead's diluted EPS also fell in Q4 compared to the previous year, though the company maintains a robust cash position of $8.4 billion, suggesting continued resilience and capacity for future growth.
Read more →GILDGilead Contacts: Jacquie Ross, Investors investor_relations@gilead.com Ashleigh Koss, Media public_affairs@gilead.com TED LOVE, MD, JOINS GILEAD SCIENCES'
Gilead Sciences has appointed Ted Love, MD, to its Board of Directors, enhancing its leadership with his extensive biopharma experience. Dr. Love, recognized for his contributions to healthcare equity, has previously led Global Blood Therapeutics and has held key positions in several biopharma companies. His appointment aligns with Gilead's commitment to access and inclusion in healthcare. Gilead's CEO expressed enthusiasm about Dr. Love's addition to the board, anticipating his valuable contributions to the company's mission.
Read more →GILDGILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV PROJECTS IN ASIA PACIFIC –2023 Gilead Asia Pacific Rainbow Grant Funding Will Support 40 Projects In 2024-2025 To Reduce HIV Stigma And Improve Equity Across Asia Pacific – – ...
Gilead Sciences has announced the allocation of over $1.5 million to support 40 community-led projects aimed at reducing HIV stigma and improving health equity across Asia Pacific. This funding is part of the Gilead Asia Pacific Rainbow Grant, which has awarded nearly $6 million since its inception in 2018. The initiative focuses on empowering underserved communities and addressing social determinants of health affecting at-risk populations. The announcement coincides with World AIDS Day, emphasizing the importance of community involvement in combating HIV.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sal
Gilead Sciences announced its third quarter financial results for 2023, reporting a flat total revenue of $7.1 billion compared to the previous year. Significant sales growth was noted in Oncology and HIV products, with Biktarvy sales up 12% year-over-year. However, Veklury sales fell by 31%, largely due to a decline in COVID-19 hospitalizations. Looking ahead, Gilead has increased its guidance for annual product sales, indicating optimism despite challenges in certain segments.
Read more →GILDByoung Chul Cho, Yonsei Cancer Center, Republic of Korea 1 DRAFT Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study Byoung Chul Cho,1 Manuel Cobo
Preliminary results from the EVOKE-02 study indicate that the combination of sacituzumab govitecan and pembrolizumab demonstrates encouraging antitumor activity in patients with first-line metastatic non-small cell lung cancer (mNSCLC). The study reported an overall response rate of 69% in patients with high PD-L1 expression and a disease control rate of 86%. Although the treatment showed a manageable safety profile, concerns were raised with one patient experiencing sepsis leading to death and two cases of grade 3 pneumonitis. The ongoing phase 3 study, EVOKE-03, will further evaluate this combination compared to pembrolizumab monotherapy.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 17% Year-Over-Year to $3.0 billion Oncology S
Gilead Sciences reported strong financial results for Q2 2023, with total revenue rising 5% to $6.6 billion. Product sales excluding Veklury grew 11% year-over-year, driven by increases in Biktarvy and oncology therapeutics. However, diluted earnings per share declined due to a significant legal settlement accrual and rising operational costs. The company remains optimistic, having received positive regulatory updates and continuing to expand its therapy portfolio.
Read more →GILDGILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030 Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of the 2023 Gilead ALL4LIVER Grant, a grant program with the theme of 'Test. Link....
Gilead Sciences has launched the 2023 ALL4LIVER Grant program to support initiatives aimed at eliminating viral hepatitis by 2030. The program will fund projects globally, excluding the U.S., focusing on testing and improving care linkage. This expansion follows the initial launch in 2021 and aims to address the urgent public health challenge posed by viral hepatitis.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion Oncology Sa
Gilead Sciences announced its first quarter 2023 financial results, showcasing a 15% year-over-year increase in product sales excluding Veklury, reaching $5.7 billion. Biktarvy and Oncology sales demonstrated notable growths of 24% and 59% respectively, largely driven by new market approvals. However, overall revenue decreased by 4% compared to the previous year, primarily due to a significant drop in Veklury sales linked to lower COVID-19 hospitalizations. Gilead anticipates total product sales for the year to remain stable despite the ongoing challenges in the market.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022 Biktarvy Sales Increased Year-Over-Year by 20% for
Gilead Sciences reported their fourth quarter and full year 2022 financial results, showcasing a notable year-over-year increase in various product sales, except for Veklury, which saw a significant decline. The total revenue for the full year remained flat at $27.3 billion, driven largely by strong performances in Oncology and HIV. While Gilead's diluted earnings per share decreased, non-GAAP diluted EPS saw a slight increase. The company emphasized its robust growth driven by successful launches and expansions, particularly in the oncology sector.
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion Oncology Sa
GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion Oncology Sales Increased 79% Year-Over-Year to $578 million Foster City, CA,
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS Biktarvy Sales Increased 28% Year-Over-Year to $2.6 billion Oncology Sales Increased 71% Year-Over-Year to $527 million Foster City, CA
GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS Biktarvy Sales Increased 28% Year-Over-Year to $2.6 billion Oncology Sales Increased 71% Year-Over-Year to $527 million Foster City, CA, August 2, 2022 - Gilead Sciences, Inc. (Nasdaq GILD) announced today its res
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS Biktarvy Sales Increased 18% Year-Over-Year to $2.2 billion Oncology Sales Increased 60% Year-Over-Year to $420 million Foster City, CA
GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS Biktarvy Sales Increased 18% Year-Over-Year to $2.2 billion Oncology Sales Increased 60% Year-Over-Year to $420 million Foster City, CA, April 28, 2022 - Gilead Sciences, Inc. (Nasdaq GILD) announced today its resu
Read more →GILDJacquie Ross, Investors investor_relations@gilead.com Nathan Kaiser, U.S. Media (650) 522-1853 Karley Ura, Global Media (416) 858-0537 CONFIDENTIAL PHASE 3 TROPiCS-02 STUDY MET THE PRIMARY ENDPOINT OF PROGRESSI
CONTACTS: Jacquie Ross, Investors investor_relations@gilead.com Nathan Kaiser, U.S. Media Karley Ura, Global Media PHASE 3 TROPiCS-02 STUDY MET THE PRIMARY ENDPOINT OF PROGRESSION- FREE SURVIVAL IN LATE-LINE HR+/HER2- METASTATIC BREAST CANCER - Study Will Continue to Follow
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Biktarvy Sales Increased Year-Over-Year by 19% for Full Year 2021 22% for Fourth Quarter 2021 EPS Results Reflect $1.25 Billion Charg
GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Biktarvy Sales Increased Year-Over-Year by 19% for Full Year 2021 22% for Fourth Quarter 2021 EPS Results Reflect $1.25 Billion Charge for a Legal Settlement $625 Million Arcus Opt-In Charge Foster C
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS 2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter Biktarvy Sales Increased 20% Year-Over-Year to
GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS 2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter Biktarvy Sales Increased 20% Year-Over-Year to Record $2.3 Billion Foster City, CA, October 28, 2021 - Gilead Sci
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS Second Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury Biktarvy Sales Increased 24% Year-Over-Year Foster City,
GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS Second Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury Biktarvy Sales Increased 24% Year-Over-Year Foster City, CA, July 29, 2021 - Gilead Sciences, Inc. (Nasdaq GILD) announced
Read more →GILDDocument GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS First Quarter 2021 Product Sales Increased 16% Year-Over-Year Primarily Driven by Veklury Returned $1.2 Billion of Cash to Shareholders in First Qua
GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS First Quarter 2021 Product Sales Increased 16% Year-Over-Year Primarily Driven by Veklury Returned $1.2 Billion of Cash to Shareholders in First Quarter 2021 Through Dividends and Share Repurchases Foster City, CA,
Read more →GILDDocument CONTACTS Investors Media Jacquie Ross Amy Flood (650) 574-3000 (650) 522-5643 For Immediate Release GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Fourth Quarter 2020 Year-Over-Yea
CONTACTS Investors Media Jacquie Ross Amy Flood (650) 574-3000 (650) 522-5643 For Immediate Release GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Fourth Quarter 2020 Year-Over-Year - Product Sales increased 26% to $7.3 billion, primarily
Read more →GILDDocument CONTACTS Investors Media Monica Tellado Amy Flood (650) 574-3000 (650) 522-5643 For Immediate Release GILEAD SCIENCES ANNOUNCES UPDATED 2020 GUIDANCE Foster City, Calif.
CONTACTS Investors Media Monica Tellado Amy Flood (650) 574-3000 (650) 522-5643 For Immediate Release GILEAD SCIENCES ANNOUNCES UPDATED 2020 GUIDANCE Foster City, Calif., January 11, 2021 - Gilead Sciences, Inc. (Nasdaq GILD) today announced the company has revised cert
Read more →GILDDouglas Maffei, PhD, Investors (650) 522-2739 Marni Kottle, Media (650) 522-5388 For Immediate Release JEFFREY A. BLUESTONE JOINS GILEAD SCIENCES' BOARD OF DIRECTORS Foster City, Calif.
For Immediate Release JEFFREY A. BLUESTONE JOINS GILEAD SCIENCES' BOARD OF DIRECTORS Foster City, Calif., December 8, 2020 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jeffrey A. Bluestone, PhD, has been appointed to the company's Board of Directors. Dr. Bluesto
Read more →GILDDocument CONTACTS Investors Media Adam Levy, MBA, Ph.D. Amy Flood (650) 574-3000 (650) 522-5643 Douglas Maffei, Ph.D. (650) 574-3000 For Immediate Release GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS Th
CONTACTS Investors Media Adam Levy, MBA, Ph.D. Amy Flood (650) 574-3000 (650) 522-5643 Douglas Maffei, Ph.D. (650) 574-3000 For Immediate Release GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS Third Quarter 2020 Highlights Year-Over-Year - Produ
Read more →GILDDouglas Maffei, PhD, Investors (650) 522-2739 Amy Flood, Media (650) 522-5643 GILEAD SCIENCES COMPLETES ACQUISITION OF IMMUNOMEDICS, INC. Foster City, Calif.
CONTACTS: Douglas Maffei, PhD, Investors Amy Flood, Media (650) 522-5643 GILEAD SCIENCES COMPLETES ACQUISITION OF IMMUNOMEDICS, INC. Foster City, Calif., October 23, 2020 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transact
Read more →GILDGilead Contacts: Immunomedics Contacts: Douglas Maffei, PhD, Investors Dr. Chau Cheng (650) 522-2739 (862) 260-3727 ccheng@immunomedics.com Amy Flood, Media Darren Opland, PhD, Media (650) 522-5643 (646) 627-8387 darren@
For Immediate Release GILEAD SCIENCES TO ACQUIRE IMMUNOMEDICS -- Gilead Adds Trodelvy TM , First-in-Class Antibody-Drug Conjugate Approved to Treat Triple- Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors -- -- Acquisition Trans
Read more →GILDDocument CONTACTS Investors Media Adam Levy, MBA, Ph.D. Amy Flood (650) 574-3000 (650) 522-5643 Douglas Maffei, Ph.D. (650) 574-3000 For Immediate Release GILEAD SCIENCES ANNOUNCES SECOND QUARTER AND FIRST HALF 2020 FINA
CONTACTS Investors Media Adam Levy, MBA, Ph.D. Amy Flood (650) 574-3000 (650) 522-5643 Douglas Maffei, Ph.D. (650) 574-3000 For Immediate Release GILEAD SCIENCES ANNOUNCES SECOND QUARTER AND FIRST HALF 2020 FINANCIAL RESULTS Second Quarter and First Half 202
Read more →GILDDouglas Maffei, PhD, Investors (650) 522-2739 Marni Kottle, Media (650) 522-5388 For Immediate Release JAVIER RODRIGUEZ JOINS GILEAD SCIENCES' BOARD OF DIRECTORS Foster City, Calif.
CONTACTS: Douglas Maffei, PhD, Investors Marni Kottle, Media For Immediate Release JAVIER RODRIGUEZ JOINS GILEAD SCIENCES' BOARD OF DIRECTORS Foster City, Calif., June 16, 2020 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Javier Rodriguez has been appointed to
Read more →GILDGILEAD SCIENCES ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS
CONTACTS: Investors Media Andrew Dickinson Amy Flood (650) 524-0862 (650) 522-5643 Douglas Maffei, Ph.D. (650) 522-2739 For Immediate Release GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS - Product Sales of $5.5 billion - - Diluted EPS of $1.22
Read more →GILDGilead Sciences, Inc. Forty Seven, Inc. Douglas Maffei, PhD, Investors Hannah Deresiewicz, Investors (650) 522-2739 (212) 362-1200 Amy Flood, Media Ann Rhoads, Investors (650) 522-5643 (650) 352-4853 Sarah Plum
GILEAD TO ACQUIRE FORTY SEVEN FOR $4.9 BILLION - Gilead Gains Forty Seven's Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma - - Transaction Supports Gi
Read more →GILDCorporate, Product and Pipeline Updates for the Fourth Quarter, Including the Announcement of:
CONTACTS: Investors Media Andrew Dickinson Amy Flood (650) 524-0862 (650) 522-5643 Douglas Maffei (650) 522-2739 For Immediate Release GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS - Fourth Quarter Product Sales of $5.8 billion -
Read more →GILDDouglas Maffei, Investors (650) 522-2739 Amy Flood, Media (650) 522-5643 For Immediate Release SANDRA HORNING, MD, JOINS GILEAD SCIENCES' BOARD OF DIRECTORS Foster City, Calif.
For Immediate Release SANDRA HORNING, MD, JOINS GILEAD SCIENCES' BOARD OF DIRECTORS Foster City, Calif., January 30, 2020 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Sandra Horning, MD, has been appointed to the company's Board of Directors. Dr. Horning retired
Read more →GILDCorporate Highlights, Including the Announcement of:
CONTACTS: Investors Media Robin Washington Amy Flood (650) 522-5688 (650) 522-5643 Sung Lee (650) 524-7792 For Immediate Release GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS - Product Sales of $5.5 billion - - GAAP Loss of $0.92 per share - -
Read more →GILDSung Lee, Investors (650) 524-7792 Marni Kottle, Media (650) 522-5388 For Immediate Release GILEAD SCIENCES APPOINTS ANDREW DICKINSON AS CHIEF FINANCIAL OFFICER Foster City, Calif.
For Immediate Release GILEAD SCIENCES APPOINTS ANDREW DICKINSON AS CHIEF FINANCIAL OFFICER Foster City, Calif., October 15, 2019 - Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Andrew Dickinson has been appointed Chief Financial Officer (CFO), effective November 1.
Read more →GILDGilead Galapagos Sung Lee, Investors Elizabeth Goodwin, Investors (650) 524-7792 (781) 460-1784 Amy Flood, Media Sofie Van Gijsel, Investors (650) 522-5643 +32 485 19 14 15 Carmen Vroonen, Media +32 473 824 874
For Immediate Release GILEAD AND GALAPAGOS COMPLETE CLOSING OF THEIR TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION Foster City, Calif. and Mechelen, Belgium -- August 23, 2019 -- Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today annou
Read more →GILDSung Lee, Investors (650) 524-7792 Amy Flood, Media (650) 522-5643 For Immediate Release GILEAD SCIENCES ANNOUNCES CHANGES TO SENIOR LEADERSHIP TEAM Foster City, Calif.
For Immediate Release GILEAD SCIENCES ANNOUNCES CHANGES TO SENIOR LEADERSHIP TEAM Foster City, Calif., July 17, 2019 Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Execu
Read more →GILDGilead Galapagos Sung Lee, Investors Elizabeth Goodwin, Investors (650) 524-7792 (781) 460-1784 Amy Flood, Media Carmen Vroonen, Media (650) 522-5643 +32 473 824 874 For Immediate Release GILEAD AND GALAPAGOS E
For Immediate Release GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment Gilead Gains Access to Galapagos Differentiated Drug Discovery Platform and Current and
Read more →GILDSung Lee, Investors 650-524-7792 Marni Kottle, Media 650-522-5388 For Immediate Release GILEAD SCIENCES APPOINTS JOHANNA MERCIER AS CHIEF COMMERCIAL OFFICER - Laura Hamill to Depart Gilead - Foster City, Calif.
For Immediate Release GILEAD SCIENCES APPOINTS JOHANNA MERCIER AS CHIEF COMMERCIAL OFFICER - Laura Hamill to Depart Gilead - Foster City, Calif., May 29, 2019 Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Johanna Mercier will join the company as Chief Commercial O
Read more →GILDSung Lee, Investors (650) 524-7792 Amy Flood, Media (650) 522-5643 For Immediate Release GILEAD SCIENCES CHIEF FINANCIAL OFFICER ROBIN WASHINGTON TO STEP DOWN IN EARLY 2020 Foster City, Calif.
For Immediate Release GILEAD SCIENCES CHIEF FINANCIAL OFFICER ROBIN WASHINGTON TO STEP DOWN IN EARLY 2020 Foster City, Calif., April 30, 2019 Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Robin Washington, Executive Vice President (EVP) and Chief Financial Officer (
Read more →GILDProduct & Pipeline Updates announced by Gilead during the Fourth Quarter of 2018 include:
CONTACTS: Investors Media Robin Washington Amy Flood (650) 522-5688 (650) 522-5643 Sung Lee (650) 524-7792 For Immediate Release GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS - Fourth Quarter Product Sales of $5.7 billion - - Fu
Read more →GILDSung Lee, Investors (650) 524-7792 For Immediate Release Amy Flood, Media (650) 522-5643 GILEAD SCIENCES NAMES DANIEL O DAY CHAIRMAN AND CHIEF EXECUTIVE OFFICER Mr. O Day Brings Global Pharmaceutical Leadership
GILEAD SCIENCES NAMES DANIEL O DAY CHAIRMAN AND CHIEF EXECUTIVE OFFICER Mr. O Day Brings Global Pharmaceutical Leadership Experience Across Geographies and Therapeutic Areas Appointment Effective March 1, 2019 Foster City, Calif., December 9, 2018 Gilead Sciences, Inc. (Nasdaq
Read more →GILDProduct and Pipeline Updates announced by Gilead during the Third Quarter of 2018 include:
CONTACTS: Investors Media Robin Washington Amy Flood (650) 522-5688 (650) 522-5643 Sung Lee (650) 524-7792 For Immediate Release GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS - Product Sales of $5.5 billion - - Diluted EPS of $1.60 per share -
Read more →GILDSung Lee, Investors (650) 524-7792 Amy Flood, Media (650) 522-5643 For Immediate Release GILEAD SCIENCES ANNOUNCES CEO JOHN F. MILLIGAN TO STEP DOWN Dr. Milligan to Remain With Company Through Year End Foster C
For Immediate Release GILEAD SCIENCES ANNOUNCES CEO JOHN F. MILLIGAN TO STEP DOWN Dr. Milligan to Remain With Company Through Year End Foster City, Calif., July 25, 2018 Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F. Milligan, PhD, will step down as Presiden
Read more →GILDProduct and Pipeline Updates announced by Gilead during the Second Quarter of 2018 include:
CONTACTS: Investors Media Robin Washington Amy Flood (650) 522-5688 (650) 522-5643 Sung Lee (650) 524-7792 For Immediate Release GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS - Product Sales of $5.5 billion - - Diluted EPS of $1.39 per share -
Read more →GILDSung Lee, Investors (650) 524-7792 Michele Rest, Media (650) 577-6935
HARISH MANWANI JOINS GILEAD SCIENCES BOARD OF DIRECTORS FOSTER CITY, Calif., May 9, 2018 Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Harish M. Manwani has been appointed to the company s Board of Directors. Mr. Manwani is a Global Executive Advisor to the private
Read more →GILDProduct and Pipeline Updates announced by Gilead during the First Quarter of 2018 include:
CONTACTS: Investors Media Robin Washington Amy Flood (650) 522-5688 (650) 522-5643 Sung Lee (650) 524-7792 For Immediate Release GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS - Product Sales of $5.0 billion - - Diluted EPS of $1.17 per share -
Read more →GILDProduct & Pipeline Updates announced by Gilead during the Fourth Quarter of 2017 include:
CONTACTS: Investors Media Robin Washington Amy Flood (650) 522-5688 (650) 522-5643 Sung Lee (650) 524-7792 For Immediate Release GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS - Fourth Quarter Product Sales of $5.8 billion - - Fu
Read more →GILDSung Lee, Investors (650) 524-7792 Michele Rest, Media (650) 577-6935 For Immediate Release JACQUELINE K. BARTON, PHD
For Immediate Release JACQUELINE K. BARTON, PHD, JOINS GILEAD SCIENCES BOARD OF DIRECTORS FOSTER CITY, Calif., February 1, 2018 Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jacqueline K. Barton, Ph.D., has been appointed to the company s Board of Directors. She pre
Read more →Competitive Position
How GILD ranks across every disease it competes inCompetitive Position is a premium feature
See how GILD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial